The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion in favour of marketing authorisation for EUSA Pharma’s antibody ch14.18/CHO, Dinutuximab beta, to treat high-risk neuroblastoma in Europe.

The antibody has been approved to treat children aged 12 months and above who have received induction chemotherapy earlier and achieved at least a partial response, as well as patients with a history of relapsed or refractory neuroblastoma. 

It should be combined with interleukin-2 (IL-2) in patients with a history of relapsed / refractory disease, and in patients who have not achieved a complete response after first line therapy. 

Neuroblastoma is the second most common solid tumour in childhood and predominantly affects children aged below five years.

University of Southampton Paediatric Oncology associate professor and consultant Dr Juliet Gray said: "Today's news is an important milestone for the neuroblastoma research and patient communities that have witnessed the positive outcomes for children treated by Dinutuximab beta in the clinical trials.

"I welcome this positive step towards a new, targeted immunotherapy that I can be confident offers improved results for this group in combination with existing therapies."

"As a clinician working with limited treatment options for those with high-risk neuroblastoma, I welcome this positive step towards a new, targeted immunotherapy that I can be confident offers improved results for this group in combination with existing therapies."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It was noted that any actively progressing disease should be stabilised by other suitable measures before treating relapsed neuroblastoma.

The latest approval means that children affected by this aggressive form of cancer now have improved access to the new Dinutuximab beta monoclonal antibody treatment.

Dinutuximab beta was initially established by Apeiron Biologics, and is currently used in Europe under a managed access programme as part of treatment regimens for high-risk neuroblastoma. EUSA holds exclusive global commercial rights to the antibody.

The antibody will be indicated for use in the 28 countries of the European Union upon approval.